Publications by authors named "Philippe Truffinet"

Claim this Profile
P
Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis.
Fredrik N Albach, Christian Geier, Christian Keicher, Maximilian G Posch, Stephan J Schreiber, Philippe Truffinet

Neurol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
Tanuja Chitnis, Brenda Banwell, Ludwig Kappos, Douglas L Arnold, Kivilcim Gücüyener, Philippe Truffinet

Mult Scler· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Patrick Vermersch, Cristina Granziera, Yang Mao-Draayer, Gary Cutter, Oleksandr Kalbus, Philippe Truffinet

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Jens Kuhle, Tanuja Chitnis, Brenda Banwell, Marc Tardieu, Douglas L Arnold, Philippe Truffinet

Mult Scler· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.
Carlo Tornatore, Heinz Wiendl, Alex L Lublin, Svend S Geertsen, Jeffrey Chavin, Philippe Truffinet

Front Neurol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Tanuja Chitnis, Brenda Banwell, Ludwig Kappos, Douglas L Arnold, Kivilcim Gücüyener, Philippe Truffinet

Lancet Neurol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
Aaron E Miller, Tomas P Olsson, Jerry S Wolinsky, Giancarlo Comi, Ludwig Kappos, Philippe Truffinet

Mult Scler Relat Disord· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.
Giancarlo Comi, Aaron E Miller, Myriam Benamor, Philippe Truffinet, Elizabeth M Poole

Mult Scler· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide.
Lily J Henson, Salman Afsar, Lynn Davenport, Annie Purvis, Elizabeth M Poole, Philippe Truffinet

Reprod Toxicol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
Sandra Vukusic, Patricia K Coyle, Stephanie Jurgensen, Philippe Truffinet, Myriam Benamor

Mult Scler· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study.
Aaron E Miller, Patrick Vermersch, Ludwig Kappos, Giancarlo Comi, Mark S Freedman, Philippe Truffinet

Mult Scler Relat Disord· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
Aaron E Miller, Xianhao Xu, Richard Macdonell, Steve Vucic, Philippe Truffinet

J Clin Neurosci· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
Mark S Freedman, Jerry S Wolinsky, Giancarlo Comi, Ludwig Kappos, Tomas P Olsson, Philippe Truffinet

Mult Scler· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO.
Maria Pia Sormani, Philippe Truffinet, Karthinathan Thangavelu, Pascal Rufi, Catherine Simonson

Neurol Neuroimmunol Neuroinflamm· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Paul O'Connor, Giancarlo Comi, Mark S Freedman, Aaron E Miller, Ludwig Kappos, Philippe Truffinet

Neurology· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Giancarlo Comi, Mark S Freedman, Ludwig Kappos, Tomas P Olsson, Aaron E Miller, Philippe Truffinet

Mult Scler Relat Disord· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.
Amit Bar-Or, Heinz Wiendl, Barry Miller, Myriam Benamor, Philippe Truffinet

Neurol Neuroimmunol Neuroinflamm· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Aaron E Miller, Jerry S Wolinsky, Ludwig Kappos, Giancarlo Comi, Mark S Freedman, Philippe Truffinet

Lancet Neurol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Patrick Vermersch, Anna Czlonkowska, Luigi M E Grimaldi, Christian Confavreux, Giancarlo Comi, Philippe Truffinet

Mult Scler· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Christian Confavreux, Paul O'Connor, Giancarlo Comi, Mark S Freedman, Aaron E Miller, Philippe Truffinet

Lancet Neurol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
Jerry S Wolinsky, Ponnada A Narayana, Flavia Nelson, Sushmita Datta, Paul O'Connor, Philippe Truffinet

Mult Scler· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.
Amit Bar-Or, Mark S Freedman, Marcelo Kremenchutzky, Françoise Menguy-Vacheron, Deborah Bauer, Philippe Truffinet

Neurology· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
Aaron E Miller, Paul O'Connor, Jerry S Wolinsky, Christian Confavreux, Ludwig Kappos, Philippe Truffinet

Mult Scler· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
Christian Confavreux, David K Li, Mark S Freedman, Philippe Truffinet, Hadj Benzerdjeb

Mult Scler· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Paul O'Connor, Jerry S Wolinsky, Christian Confavreux, Giancarlo Comi, Ludwig Kappos, Philippe Truffinet

N Engl J Med· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis